Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Meeker AK, Hicks JL, Iacobuzio-Donahue CA et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 10(10), 3317–3326 (2004).
  Medline CASGoogle Scholar
• 2 D'adda Di Fagagna F, Reaper PM, Clay-Farrace L et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426(6963), 194–198 (2003).
  MedlineGoogle Scholar
• 3 Meeker AK, Gage WR, Hicks JL et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am. J. Pathol. 160(4), 1259–1268 (2002).
  Medline CASGoogle Scholar
• 4 Takai H, Smogorzewska A, De Lange T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 13(17), 1549–1556 (2003).
  Medline CASGoogle Scholar
• 5 Rudolph KL, Hartmann D, Opitz OG. Telomere dysfunction and DNA damage checkpoints in diseases and cancer of the gastrointestinal tract. Gastroenterology 137(3), 754–762 (2009).
  Medline CASGoogle Scholar
• 6 Bilsland AE, Revie J, Keith WN. MicroRNA and senescence: the senectome, integration and distributed control. Crit. Rev. Oncog. 18(4), 373–390 (2013).
  MedlineGoogle Scholar
• 7 Cairney CJ, Bilsland AE, Evans TR et al. Cancer cell senescence: a new frontier in drug development. Drug Discov. Today 17(5–6), 269–276 (2012).
  Medline CASGoogle Scholar
• 8 Jiang H, Schiffer E, Song Z et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc. Natl Acad. Sci. USA 105(32), 11299–11304 (2008). •• Describes first identification of NAG as a factor secreted in response to DNA damage and cellular senescence.
  Medline CASGoogle Scholar
• 9 Scott LC, Evans TR, Cassidy J et al. Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br. J. Cancer 101(3), 410–417 (2009).
  Medline CASGoogle Scholar
• 10 James K, Eisenhauer E, Christian M et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J. Natl Cancer Inst. 91(6), 523–528 (1999).
  Medline CASGoogle Scholar
• 11 Song Z, Von Figura G, Liu Y et al. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell 9(4), 607–615 (2010).
  Medline CASGoogle Scholar
• 12 Watabe-Rudolph M, Song Z, Lausser L et al. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 78(8), 569–577 (2012). • Related DNA damage marker chitotriosidase identified as a candidate marker of Alzheimer's disease.
  Medline CASGoogle Scholar
• 13 Jeyapalan JC, Sedivy JM. Cellular senescence and organismal aging. Mech. Ageing Dev. 129(7–8), 467–474 (2008).
  Medline CASGoogle Scholar
• 14 Lafferty-Whyte K, Bilsland A, Cairney CJ et al. Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics 11, 532 (2010).
  MedlineGoogle Scholar
• 15 Sikora E, Arendt T, Bennett M, Narita M. Impact of cellular senescence signature on ageing research. Ageing Res. Rev. 10(1), 146–152 (2010).
  MedlineGoogle Scholar
• 16 Ma H, Zhou Z, Wei S et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS ONE 6(6), e20466 (2011).
  Medline CASGoogle Scholar
• 17 Mu Y, Zhang Q, Mei L, Liu X, Yang W, Yu J. Telomere shortening occurs early during gastrocarcinogenesis. Med. Oncol. 29(2), 893–898 (2012).
  Medline CASGoogle Scholar
• 18 Pooley KA, Sandhu MS, Tyrer J et al. Telomere length in prospective and retrospective cancer case-control studies. Cancer Res. 70(8), 3170–3176 (2010).
  Medline CASGoogle Scholar